Literature DB >> 27608668

Priming HIV-1 broadly neutralizing antibody precursors in human Ig loci transgenic mice.

Devin Sok1, Bryan Briney1, Joseph G Jardine1, Daniel W Kulp1, Sergey Menis1, Matthias Pauthner1, Andrew Wood2, E-Chiang Lee2, Khoa M Le1, Meaghan Jones1, Alejandra Ramos1, Oleksandr Kalyuzhniy1, Yumiko Adachi1, Michael Kubitz1, Skye MacPherson1, Allan Bradley3, Glenn A Friedrich2, William R Schief4, Dennis R Burton4.   

Abstract

A major obstacle to a broadly neutralizing antibody (bnAb)-based HIV vaccine is the activation of appropriate B cell precursors. Germline-targeting immunogens must be capable of priming rare bnAb precursors in the physiological setting. We tested the ability of the VRC01-class bnAb germline-targeting immunogen eOD-GT8 60mer (60-subunit self-assembling nanoparticle) to activate appropriate precursors in mice transgenic for human immunoglobulin (Ig) loci. Despite an average frequency of, at most, about one VRC01-class precursor per mouse, we found that at least 29% of singly immunized mice produced a VRC01-class memory response, suggesting that priming generally succeeded when at least one precursor was present. The results demonstrate the feasibility of using germline targeting to prime specific and exceedingly rare bnAb-precursor B cells within a humanlike repertoire.
Copyright © 2016, American Association for the Advancement of Science.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27608668      PMCID: PMC5404394          DOI: 10.1126/science.aah3945

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  47 in total

1.  Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1.

Authors:  Marie Pancera; Jason S McLellan; Xueling Wu; Jiang Zhu; Anita Changela; Stephen D Schmidt; Yongping Yang; Tongqing Zhou; Sanjay Phogat; John R Mascola; Peter D Kwong
Journal:  J Virol       Date:  2010-06-10       Impact factor: 5.103

2.  Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization.

Authors:  Florian Klein; Ron Diskin; Johannes F Scheid; Christian Gaebler; Hugo Mouquet; Ivelin S Georgiev; Marie Pancera; Tongqing Zhou; Reha-Baris Incesu; Brooks Zhongzheng Fu; Priyanthi N P Gnanapragasam; Thiago Y Oliveira; Michael S Seaman; Peter D Kwong; Pamela J Bjorkman; Michel C Nussenzweig
Journal:  Cell       Date:  2013-03-28       Impact factor: 41.582

3.  Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1.

Authors:  Xueling Wu; Zhi-Yong Yang; Yuxing Li; Carl-Magnus Hogerkorp; William R Schief; Michael S Seaman; Tongqing Zhou; Stephen D Schmidt; Lan Wu; Ling Xu; Nancy S Longo; Krisha McKee; Sijy O'Dell; Mark K Louder; Diane L Wycuff; Yu Feng; Martha Nason; Nicole Doria-Rose; Mark Connors; Peter D Kwong; Mario Roederer; Richard T Wyatt; Gary J Nabel; John R Mascola
Journal:  Science       Date:  2010-07-08       Impact factor: 47.728

4.  HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen.

Authors:  Joseph G Jardine; Takayuki Ota; Devin Sok; Matthias Pauthner; Daniel W Kulp; Oleksandr Kalyuzhniy; Patrick D Skog; Theresa C Thinnes; Deepika Bhullar; Bryan Briney; Sergey Menis; Meaghan Jones; Mike Kubitz; Skye Spencer; Yumiko Adachi; Dennis R Burton; William R Schief; David Nemazee
Journal:  Science       Date:  2015-06-18       Impact factor: 47.728

5.  Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies.

Authors:  Nicole A Doria-Rose; Chaim A Schramm; Jason Gorman; Penny L Moore; Jinal N Bhiman; Brandon J DeKosky; Michael J Ernandes; Ivelin S Georgiev; Helen J Kim; Marie Pancera; Ryan P Staupe; Han R Altae-Tran; Robert T Bailer; Ema T Crooks; Albert Cupo; Aliaksandr Druz; Nigel J Garrett; Kam H Hoi; Rui Kong; Mark K Louder; Nancy S Longo; Krisha McKee; Molati Nonyane; Sijy O'Dell; Ryan S Roark; Rebecca S Rudicell; Stephen D Schmidt; Daniel J Sheward; Cinque Soto; Constantinos Kurt Wibmer; Yongping Yang; Zhenhai Zhang; James C Mullikin; James M Binley; Rogier W Sanders; Ian A Wilson; John P Moore; Andrew B Ward; George Georgiou; Carolyn Williamson; Salim S Abdool Karim; Lynn Morris; Peter D Kwong; Lawrence Shapiro; John R Mascola
Journal:  Nature       Date:  2014-03-02       Impact factor: 49.962

6.  Broad neutralization coverage of HIV by multiple highly potent antibodies.

Authors:  Laura M Walker; Michael Huber; Katie J Doores; Emilia Falkowska; Robert Pejchal; Jean-Philippe Julien; Sheng-Kai Wang; Alejandra Ramos; Po-Ying Chan-Hui; Matthew Moyle; Jennifer L Mitcham; Phillip W Hammond; Ole A Olsen; Pham Phung; Steven Fling; Chi-Huey Wong; Sanjay Phogat; Terri Wrin; Melissa D Simek; Wayne C Koff; Ian A Wilson; Dennis R Burton; Pascal Poignard
Journal:  Nature       Date:  2011-09-22       Impact factor: 49.962

7.  Clonify: unseeded antibody lineage assignment from next-generation sequencing data.

Authors:  Bryan Briney; Khoa Le; Jiang Zhu; Dennis R Burton
Journal:  Sci Rep       Date:  2016-04-22       Impact factor: 4.379

8.  Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens.

Authors:  Xiaodong Xiao; Weizao Chen; Yang Feng; Zhongyu Zhu; Ponraj Prabakaran; Yanping Wang; Mei-Yun Zhang; Nancy S Longo; Dimiter S Dimitrov
Journal:  Biochem Biophys Res Commun       Date:  2009-09-11       Impact factor: 3.575

9.  A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies.

Authors:  Rogier W Sanders; Ronald Derking; Albert Cupo; Jean-Philippe Julien; Anila Yasmeen; Natalia de Val; Helen J Kim; Claudia Blattner; Alba Torrents de la Peña; Jacob Korzun; Michael Golabek; Kevin de Los Reyes; Thomas J Ketas; Marit J van Gils; C Richter King; Ian A Wilson; Andrew B Ward; P J Klasse; John P Moore
Journal:  PLoS Pathog       Date:  2013-09-19       Impact factor: 6.823

10.  Minimally Mutated HIV-1 Broadly Neutralizing Antibodies to Guide Reductionist Vaccine Design.

Authors:  Joseph G Jardine; Devin Sok; Jean-Philippe Julien; Bryan Briney; Anita Sarkar; Chi-Hui Liang; Erin A Scherer; Carole J Henry Dunand; Yumiko Adachi; Devan Diwanji; Jessica Hsueh; Meaghan Jones; Oleksandr Kalyuzhniy; Michael Kubitz; Skye Spencer; Matthias Pauthner; Karen L Saye-Francisco; Fabian Sesterhenn; Patrick C Wilson; Denise M Galloway; Robyn L Stanfield; Ian A Wilson; Dennis R Burton; William R Schief
Journal:  PLoS Pathog       Date:  2016-08-25       Impact factor: 6.823

View more
  72 in total

Review 1.  What Are the Most Powerful Immunogen Design Vaccine Strategies? Reverse Vaccinology 2.0 Shows Great Promise.

Authors:  Dennis R Burton
Journal:  Cold Spring Harb Perspect Biol       Date:  2017-11-01       Impact factor: 10.005

2.  Immunization-Elicited Broadly Protective Antibody Reveals Ebolavirus Fusion Loop as a Site of Vulnerability.

Authors:  Xuelian Zhao; Katie A Howell; Shihua He; Jennifer M Brannan; Anna Z Wec; Edgar Davidson; Hannah L Turner; Chi-I Chiang; Lin Lei; J Maximilian Fels; Hong Vu; Sergey Shulenin; Ashley N Turonis; Ana I Kuehne; Guodong Liu; Mi Ta; Yimeng Wang; Christopher Sundling; Yongli Xiao; Jennifer S Spence; Benjamin J Doranz; Frederick W Holtsberg; Andrew B Ward; Kartik Chandran; John M Dye; Xiangguo Qiu; Yuxing Li; M Javad Aman
Journal:  Cell       Date:  2017-05-18       Impact factor: 41.582

3.  Glycosylation of the core of the HIV-1 envelope subunit protein gp120 is not required for native trimer formation or viral infectivity.

Authors:  Ujjwal Rathore; Piyali Saha; Sannula Kesavardhana; Aditya Arun Kumar; Rohini Datta; Sivasankar Devanarayanan; Raksha Das; John R Mascola; Raghavan Varadarajan
Journal:  J Biol Chem       Date:  2017-04-26       Impact factor: 5.157

Review 4.  How HIV-1 entry mechanism and broadly neutralizing antibodies guide structure-based vaccine design.

Authors:  Marie Pancera; Anita Changela; Peter D Kwong
Journal:  Curr Opin HIV AIDS       Date:  2017-05       Impact factor: 4.283

5.  Germline-Encoded Affinity for Cognate Antigen Enables Vaccine Amplification of a Human Broadly Neutralizing Response against Influenza Virus.

Authors:  Maya Sangesland; Larance Ronsard; Samuel W Kazer; Julia Bals; Seyhan Boyoglu-Barnum; Ashraf S Yousif; Ralston Barnes; Jared Feldman; Maricel Quirindongo-Crespo; Patrick M McTamney; Daniel Rohrer; Nils Lonberg; Bryce Chackerian; Barney S Graham; Masaru Kanekiyo; Alex K Shalek; Daniel Lingwood
Journal:  Immunity       Date:  2019-09-25       Impact factor: 31.745

Review 6.  Current views on the potential for development of a HIV vaccine.

Authors:  Kristen W Cohen; Nicole Frahm
Journal:  Expert Opin Biol Ther       Date:  2017-01-23       Impact factor: 4.388

7.  Epitope-focused immunogens against the CD4-binding site of HIV-1 envelope protein induce neutralizing antibodies against auto- and heterologous viruses.

Authors:  Hua Wang; Xiangjun Chen; Dianhong Wang; Chen Yao; Qian Wang; Jiayu Xie; Xuanling Shi; Ye Xiang; Wanli Liu; Linqi Zhang
Journal:  J Biol Chem       Date:  2017-11-29       Impact factor: 5.157

Review 8.  Human Ig knockin mice to study the development and regulation of HIV-1 broadly neutralizing antibodies.

Authors:  Laurent Verkoczy; Frederick W Alt; Ming Tian
Journal:  Immunol Rev       Date:  2017-01       Impact factor: 12.988

9.  Impact of early life exposure to ionizing radiation on influenza vaccine response in an elderly Japanese cohort.

Authors:  Tomonori Hayashi; Heather E Lynch; Susan Geyer; Kengo Yoshida; Keiko Furudoi; Keiko Sasaki; Yukari Morishita; Hiroko Nagamura; Mayumi Maki; Yiqun Hu; Ikue Hayashi; Seishi Kyoizumi; Yoichiro Kusunoki; Waka Ohishi; Saeko Fujiwara; Munechika Misumi; Ivo Shterev; Janko Nikolich-Žugich; Donna Murasko; Laura P Hale; Gregory D Sempowski; Kei Nakachi
Journal:  Vaccine       Date:  2018-09-28       Impact factor: 3.641

10.  Glycan Masking Focuses Immune Responses to the HIV-1 CD4-Binding Site and Enhances Elicitation of VRC01-Class Precursor Antibodies.

Authors:  Hongying Duan; Xuejun Chen; Jeffrey C Boyington; Cheng Cheng; Yi Zhang; Alexander J Jafari; Tyler Stephens; Yaroslav Tsybovsky; Oleksandr Kalyuzhniy; Peng Zhao; Sergey Menis; Martha C Nason; Erica Normandin; Maryam Mukhamedova; Brandon J DeKosky; Lance Wells; William R Schief; Ming Tian; Frederick W Alt; Peter D Kwong; John R Mascola
Journal:  Immunity       Date:  2018-07-31       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.